Köpenysejtes limfóma: vizsgálatok itt: Kína
41 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleRelmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
- Where
- Guangzhou
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Sun Yat-sen University
See details and how to joinNCT07077512 - 4. fázisNot yet taking people in KínaZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
- Where
- Zhengzhou
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Zhengzhou University
See details and how to joinNCT07264894 - No phaseTaking peoplePomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 34
- Run by
- Peking University Third Hospital
See details and how to joinNCT07257510 - 2. fázisNot yet taking people in KínaChemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
- Where
- Fuzhou, Harbin, Jinan, Shijiazhuang, Tianjin
- Életkor
- 60 év and over
- People
- 45
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07206264 - 2. fázisTaking peopleOrelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
- Where
- Shanghai
- Életkor
- 14 év and over
- People
- 45
- Run by
- Ruijin Hospital
See details and how to joinNCT07199296 - 1. fázisNot yet taking people in KínaJWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 20
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT07024147 - 2. fázisTaking peopleAcalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 50
- Run by
- Sun Yat-sen University
See details and how to joinNCT06846489 - 1. fázisTaking peopleSequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 52
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06464861 - 3. fázisTaking peopleA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Where
- Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Ürümqi, Wuhan, Xi'an, Yibin, Zhengzhou
- Életkor
- 60 év and over
- People
- 476 worldwide
- Run by
- InnoCare Pharma Inc.
See details and how to joinNCT06363994 · EU 2025-524241-27-00 - 2. fázisTaking peopleA Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 52
- Run by
- Fudan University
See details and how to joinNCT06341556 - 3. fázisTaking peopleBendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 78
- Run by
- Ruijin Hospital
See details and how to joinNCT06496308 - 2. fázisNot yet taking people in KínaLinperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
- Where
- Dalian
- Életkor
- 18 év and over
- People
- 10
- Run by
- Dalian Medical University
See details and how to joinNCT06324994 - 2. fázisNot yet taking people in KínaA Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
- Where
- Taiyuan
- Életkor
- 18 év to 70 év
- People
- 23
- Run by
- Shanxi Province Cancer Hospital
See details and how to joinNCT06255704 - 2. fázisTaking peopleA Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 23
- Run by
- Ruijin Hospital
See details and how to joinNCT06136351 - 2. fázisTaking peopleZR2 Sequential Immunochemotherapy for Newly Treated MCL
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 48
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT05992597 - No phaseTaking peopleA Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
- Where
- Zhengzhou
- Életkor
- 18 év to 90 év
- People
- 100
- Run by
- Zhengzhou University
See details and how to joinNCT05506410